Esophageal adenocarcinoma incidence: Are we reaching the peak?

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 6, 2010, Pages 1468-1470

  Pohl, Heiko ^a,b   Sirovich, Brenda ^a,b   Welch, H Gilbert ^a,b  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER STAGING; DATA BASE; ESOPHAGEAL ADENOCARCINOMA; HUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; ADENOCARCINOMA; CANCER REGISTRY; ESOPHAGEAL NEOPLASMS; FEMALE; INCIDENCE; MALE; PATHOLOGY; RISK FACTOR;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MALE; NEOPLASM STAGING; RISK FACTORS; SEER PROGRAM;

EID: 77953307285     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0012     Document Type: Article

References (18)

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-6.
2. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-51.
3. Joinpoint Regression Program. National Cancer Institute, 2010 (accessed 03/12/2010, at http://srab.cancer.gov/joinpoint/).
4. Blot WJ, Devesa SS, Fraumeni JF, Jr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 1993;270:1320.
5. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
6. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009;155: 3801-7.
7. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-94.
8. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312: 1604-8.
9. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
10. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:872-8.
11. Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009; 7:1299-304.
12. Fortuny J, Johnson CC, Bohlke K, et al. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol 2007; 5:1154-9 e3.
13. Rice TW. Pro: esophagectomy is the treatment of choice for high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol 2006; 101:2177-9.
14. DeMeester SR. New options for the therapy of Barrett's high-grade dysplasia and intramucosal adenocarcinoma: endoscopic mucosal resection and ablation versus vagal-sparing esophagectomy. Ann Thorac Surg 2008;85:S747-50.
15. Larghi A, Lightdale CJ, Ross AS, et al. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy 2007;39:1086-91.
16. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360: 2277-88.
17. Konda VJ, Ross AS, Ferguson MK, et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated? Clin Gastroenterol Hepatol 2008;6: 159-64.
18. Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008;67:394-8.